AHN Targets Cancer's Fibrotic Burden

2026-10-17

Cancer treatment has another adversary. AHN Cancer Center has launched RANDY'S Trial to test FDA-approved drugs against peritoneal fibrosis in abdominal cancer patients, directing attention toward scarring rather than the tumor alone. The distinction deserves attention. Although the drugs already have regulatory approval, their usefulness for this condition remains a question that the trial must answer.

Scar tissue is not passive. Peritoneal fibrosis involves excessive extracellular matrix accumulation, including collagen deposition, in the membrane that lines the abdominal cavity and covers many abdominal organs. Structure can become obstruction. When fibrotic tissue thickens or restricts movement, it can interfere with normal organ function, although the consequences depend on the location and extent of disease. Biology complicates the proposition. A medicine's established use does not demonstrate that it can alter these processes in patients with abdominal cancer, whose illness and other treatments may affect both tolerability and response.

Repurposing offers no automatic shortcut. Testing existing medicines can draw on information about their established uses, but any benefit against peritoneal fibrosis still requires evidence specific to the patients and condition being studied. Outcomes must earn confidence. The supplied announcement identifies the trial's purpose without specifying drug names, enrollment targets, eligibility criteria, or measures of success, so those details should not be assumed. Restraint serves patients better. For now, RANDY'S Trial represents an effort to investigate an unmet treatment question, not proof that an effective therapy has arrived. The tumor is not the whole story.

Recommendations